Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46,498 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J. Zurita AJ, et al. Among authors: li g. JCO Precis Oncol. 2022 Jul;6:e2200195. doi: 10.1200/PO.22.00195. JCO Precis Oncol. 2022. PMID: 35820087 Free PMC article.
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N, Mathew Thomas V, Oxnard GR, Antonarakis ES, Agarwal N. Swami U, et al. Among authors: li g. Clin Cancer Res. 2022 Nov 14;28(22):4917-4925. doi: 10.1158/1078-0432.CCR-22-2228. Clin Cancer Res. 2022. PMID: 36088616
Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.
Schwartzberg LS, Li G, Tolba K, Bourla AB, Schulze K, Gadgil R, Fine A, Lofgren KT, Graf RP, Oxnard GR, Daniel D. Schwartzberg LS, et al. Among authors: li g. JTO Clin Res Rep. 2022 Aug 2;3(9):100386. doi: 10.1016/j.jtocrr.2022.100386. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36089920 Free PMC article.
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha JCF, Graf RP, Fisher VA, Oxnard GR, Ellis H, Panarelli N, Lin DI, Li G, Huang RSP, Ross JS, Myer PA, Klempner SJ. Quintanilha JCF, et al. Among authors: li g. JAMA Netw Open. 2023 Jan 3;6(1):e2252244. doi: 10.1001/jamanetworkopen.2022.52244. JAMA Netw Open. 2023. PMID: 36689222 Free PMC article.
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
Hill BL, Graf RP, Shah K, Danziger N, Lin DI, Quintanilha J, Li G, Haberberger J, Ross JS, Santin AD, Slomovitz B, Elvin JA, Eskander RN. Hill BL, et al. Among authors: li g. Int J Gynecol Cancer. 2023 Apr 3;33(4):504-513. doi: 10.1136/ijgc-2022-004026. Int J Gynecol Cancer. 2023. PMID: 36750267 Free PMC article. Clinical Trial.
Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
Quintanilha JCF, Storandt MH, Graf RP, Li G, Keller R, Lin DI, Ross JS, Huang RSP, Schrock AB, Oxnard GR, Chakrabarti S, Mahipal A. Quintanilha JCF, et al. Among authors: li g. JCO Precis Oncol. 2023 Jul;7:e2300092. doi: 10.1200/PO.23.00092. JCO Precis Oncol. 2023. PMID: 37410975 Free PMC article.
46,498 results
You have reached the last available page of results. Please see the User Guide for more information.